Trials / Conditions / Breast Cancer Recurrent

Breast Cancer Recurrent

18 registered clinical trials studyying Breast Cancer Recurrent — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tu NCT06799065	Accent Therapeutics	Phase 1
Recruiting	Thermotherapy in Addition to SOC Palliative Radiotherapy NCT06659146	King's College London	N/A
Terminated	First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumo NCT06625515	Accent Therapeutics	Phase 1
Recruiting	Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer NCT06458413	Min Yan, MD	Phase 2
Not Yet Recruiting	Registry of Local Recurrences After Breast-conserving Surgery NCT05406661	Universidade do Porto	—
Recruiting	Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) NCT05592938	University Health Network, Toronto	N/A
Recruiting	18F-FDG PET/CT Imaging for Breast Cancer NCT05730608	Vestre Viken Hospital Trust	N/A
Recruiting	Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082	University of Utah	Phase 2
Completed	Prolonged Nightly Fasting in Breast Cancer Survivors NCT04330339	Massachusetts General Hospital	N/A
Active Not Recruiting	Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer NCT03820830	ETOP IBCSG Partners Foundation	Phase 3
Completed	Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metas NCT05301530	Nanogen Pharmaceutical Biotechnology Joint Stock Company	Phase 1
Completed	Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cance NCT05301010	Nanogen Pharmaceutical Biotechnology Joint Stock Company	Phase 3
Completed	Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer NCT02844335	Fuda Cancer Hospital, Guangzhou	Phase 1 / Phase 2
Unknown	EpCAM CAR-T for Treatment of Advanced Solid Tumors NCT02915445	Sichuan University	Phase 1
Completed	GISEL:Registry of Breast Cancer Patients Treated With ECT NCT06683404	Istituto Oncologico Veneto IRCCS	—
Unknown	S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Can NCT02947061	Chinese Academy of Medical Sciences	Phase 2
Completed	Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizum NCT02248571	iOMEDICO AG	Phase 4
Completed	Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT NCT01552655	Odense University Hospital	N/A